Background: The aim of this cross-sectional study was to establish an online inflammatory bowel disease (IBD) registry for a first picture of the situation of IBD outpatients' treatment in Germany.
Introduction
Crohn's disease (CD) and ulcerative colitis (UC) belong to the group of inflammatory bowel diseases (IBD). Both diseases are characterised by a variable course, with phases of flares and remission or with chronic activity. In Germany, there are about 320,000 IBD patients at present, split approximately evenly between CD-and UC patients. [1] [2] [3] From a healthcare point of view, inflammatory bowel diseases (IBD) are of special relevance in particular, since they are life-long diseases which frequently develop in young patients between the ages of 15-35, and thus not only permanently affect the patient's general health, but also the working capacity of these relatively young patients. 4 International 2 and national guidelines 3 suggest a need for further research concerning health care for IBD patients. A national evidence-based and interdisciplinarily consented health-care guideline for IBD patients in Germany provides a structured framework (health-care pathways) concerning integrated treatment and care, but also revealing a considerable need for further research and large databases to allow for further development of guidelines. 5 So far, epidemiologic data and reference data concerning health care are widely missing for the population of IBD patients in Germany. Data of previous regional German cohorts [6] [7] [8] [9] [10] [11] show a need for multiregional registry data in Germany. The objective of the current study is to utilize a large registry cohort of IBD patients to offer reference data concerning clinical status, psychosocial impairments, health care and medication as well as health care costs of these patients in Germany with a focus on the burden of active disease. A recent study provided evidence for associations of disease activity and psychosocial impairments in IBD patients in Germany with medication schemes. 12 A multi-regional postal survey on the situation of IBD patients in Germany 13 revealed a substantial psychosocial burden for inflammatory bowel diseases with high prevalences of reported mental health symptoms and severe suffering from the diseases. The survey provided first evidence on the high psychosocial impairments in IBD patients probably resulting from disease activity, adverse effects of health care (diagnostics, treatment) and the burden of an often lifelong chronic disease. These impairments affect dailylife activities and participation restrictions according to the understanding of chronic diseases following the International Classification of Functioning, Disability and Health (ICF). 14 The ICF concepts of psychosocial impairments in chronic patients have motivated the development of standardised questionnaires for large studies in patient populations, e.g. the German IMET questionnaire. 15 This index for measuring restrictions in participation developed on the basis of the Pain Disability Index (PDI) 16, 17 was administered in this online registry and previously shown to be associated with disease activity. 18 According to the latest years' gathered evidence, 2 stress perceived by IBD patients may trigger disease activity, but psychosocial impairments in IBD are rather to be understood as accompanying symptoms and a consequence of considerable disease activity as well as being impaired by a lifelong chronic disease than as risk factors of the disease (cf. ECCO statements 12A-D).
Psychosocial aspects of the chronic disease will be included here only as brief indicators to give a comprehensive description of the registry cohort of IBD patients and in the analyses of covariates for disease activity. Furthermore, they are exemplarily examined in an exploratory multivariate analysis for possible predictors and confounding with regard to two cardinal symptoms of psychosocial impairments in IBD patients 13 : depressive mood and sexual problems.
This basic publication of the online registry presents an overview of the registry cohort, the collected data and the scope of research questions related to the registry data including a comprehensive discussion. Additional and more specific research questions will be analysed in complementing publications. Detailed analyses of medication costs from a health economical point of view have been published earlier 4, 19, 20 and detailed analyses of the psychosocial aspects of inflammatory bowel diseases will be described in further publications.
Methods

Data recruitment
This cross-sectional study was carried out between March 2006 and July 2007. Twenty-four gastroenterological practices specialising in IBD and two outpatient hospital departments consecutively documented IBD patients in an Internet-based (online) registry, which recorded clinical status (including involvement pattern and disease activity), medical treatments, prior examinations performed and inpatient treatment, as well as psychosocial impairments. All data were gathered pseudonymised in an online documentation sheet.
The quality of data input was verified for completeness and correctness by means of an input logic and all patient data were electronically saved by IOMTech GmbH in Berlin, Germany. Ethics approval was obtained from the University of Münster Ethics Commission with respect to this principle of an Internet-based pseudonymised documentation of IBD patients.
Questionnaire
The online documentation sheet comprised questions on patient characteristics (demographic data, domicile, insurance status, smoking habits, body-mass index), an anamnesis of the disease, involvement patterns, prior treatment, current laboratory values as well as disease activity scores (activity indices: Colitis Activity Index/CAI; Crohn's Disease Activity Index/CDAI) and additional queries regarding endoscopic and other diagnostic follow-up examinations. Further, a global assessment of the physician concerning disease activity (PGA) and detailed information on medication were requested. Established standardised questionnaire instruments were used to survey psychosocial impairments of the registry patients. These instruments comprised a single item (general health perception) and two scales (vitality, mental health) of the SF-36 questionnaire. 21 Two items each were used from the SF-36 vitality-(Did you feel … "…tired?", "… worn out") and the mental health scale (Did you feel …" … downhearted?", "… so depressed that nothing could cheer you up?") to analyse psychological aspects of disease activity. These four items each score from "none …" to "all of the time" (1 to 6 points) and refer to the past 4 weeks.
A single item (impairments in sexuality) from the IMET questionnaire 15 was included in the analyses reported here for a brief description of this vital aspect of chronic disease impairments 13 in association with disease activity. A new IMET version with five answer categories (not at all -a little -considerable -strong -very strong) was applied in this registry.
Statistical analyses
Data analyses comprise descriptive analyses with results given as frequencies (numbers and percentages) for categorical variables as well as means and standard deviations for metric variables. Chi-square tests for frequencies and t-tests for means were applied to complement inferential statistical analyses (p-values reported) for group comparisons (UC vs. CD; active disease vs. remission). Covariates of disease activity are presented with stratification for subgroups and continuous variables are presented with means and differences as well as categorised to allow for revelation of possible confounding effects.
The clinical status as stated by the physician's global assessment (PGA) was checked for accordance with the cut-offs of the disease activity indices to evaluate its performance as a possible short indicator.
Uni-and multivariate binomial logistic regression analyses were implied to analyse differences between patients with active disease and remission with regard to involvement patterns, gender, age, disease duration and tobacco smoking to allow the control for possible confounders. Results of the logistic regression analyses are reported with odds ratios (OR) and 95%-confidence intervals (95%-CI), model fit indices (Nagelkerke's R-square) are reported for optimised multivariate models.
Inferential statistical analyses were applied aiming for explorative analyses of group comparisons (chi-square tests, t-tests and logistic regression analyses). The number of group comparisons implies the statistical threat of alpha cumulation and the large size of the registry cohort implies an overestimation of significant effects. As an approximation for a Bonferroni correction, p-values of b.001 will be interpreted as significant effects.
The cost of prescribed medication was assessed via official remuneration schemes. Statistical analyses were conducted with established statistics programs (Microsoft Excel ® 2007 and IBM SPSS Statistics 20 ® ).
Results
Within the framework of this cross-sectional study, 1032 IBD-patients (ulcerative colitis: 519; Crohn's disease: 511; indeterminate colitis: 2) were included in the study. Table 1 shows demographic and clinical characteristics of the UC-and CD patients in this patient cohort as well as medication and psychosocial impairments. Tables 2 and 3 show these indicators and further involvement patterns separately for UC and CD, each in comparison for patients with active disease and in remission. Table 4 then shows the results of the uni-and multivariate regression analyses to examine different predictors of disease activity for UC and CD patients with adjustment for potential confounders.
The average age of the patients was 43 years, with an average disease duration of about ten years (Table 1) . According to the medical history, 33.5% CD patients underwent a bowel resection which is more frequent than in UC patients (3.7%). In both groups, carcinomas were reported with similar frequency (UC: 2.6% and CD: 1.4%). On average, 60.9% of the patients were in clinical remission (physician's global assessment). In the past 12 months hospital admissions were reported more often in CD-(33.1%) than in UC patients (21.1%).
Out of 519 UC patients (49% male; 33% pancolitis), 66.5% were in remission (CAI ≤ 4) and out of 511 CD patients (37% male), 54.8% were in remission (CDAI b 150). The subcohorts of UC and CD patients significantly differed with regard to gender proportions, age and disease duration. CD patients were predominantly female and younger, but featured longer disease durations and more often signs of inflammation (CRP) and disease activity (Table 1) . Gender proportions and disease duration did not and age did differ slightly between UC patients with active disease (CAI N4) vs. in remission (Table 2) . However, CD patients with active disease (CDAI ≥ 150) were significantly younger, more often female and featured longer disease durations (Table 3) . These interaction effects of sociodemographic variables, disease type and -activity require multivariate analyses for the comparisons of patients with disease activity vs. remission.
UC patients were significantly more often obese than CD patients (47.8 vs. 36.9%, Table 1 ). The percentage of obese persons in UC patients did not differ by disease activity (Table 2) , however did so in CD patients (Table 3) . Patients with active Crohn's disease were less often obese and more often smoking than CD patients in remission (considerable, but non-significant).
Apart from demographic and clinical data, standardised questionnaires were also used to record the psychosocial burden of these chronic diseases for the IBD patients. As shown in Table 1 , registry patients with Crohn's disease reported impairments in their general health, vitality and mental health as well as sexuality significantly more often than UC patients.
These psychosocial factors, involvement patterns, medication and some clinical parameters of UC and CD patients are presented by clinical activity (CAI or CDAI, dichotomised at established cut-off values) in Table 2 for ulcerative colitis and in Table 3 for Crohn's disease. The levels of activity indices (CAI and CDAI) showed fair to good concordance with the clinical assessment (physician's global assessment) and the CRP value (Tables 1-4) .
Immunosuppressive therapy is used more often in CD (47.2%) than in UC (25.6%). In CD corticosteroid therapy and in UC corticosteroids and topical therapy are associated with higher rates of active disease (Figs. 1 and 2) . In active disease CRP levels are significantly higher in CD (2.1 vs. 1.0 mg/dl) and in UC (2.3 vs. 0.6 mg/dl), but only 37.2% of active CD patients and 37.9% of active CU patients have a CRP level higher than 0.6 mg/dl. Surprisingly, 41.4% of the CD patients were active smokers, whereas only 12.5% of the UC patients smoked, despite of the known unfavourable effect of smoking in CD. But in CD patients, smoker and non-smoker rates did not differ significantly for patients with active disease vs. in remission.
The results of the logistic regression analyses (Table 4 ) showed a relevant effect of smoking as a predictor for disease activity (CAI N 4/CDAI ≥150) in UC (OR = 1.24) and CD patients (OR = 1.28), which was reduced for UC patients (OR = 1.14), but increased for CD patients (OR = 1.33) after adjustment for basic confounders and involvement patterns in the multivariate analyses. However, none of these effects is significant (95%-CIs) in this registry cohort.
Depending on the disease and the status of clinical activity, severe depressive symptoms were reported by 14.9% of all patients (SF-36, item 9c "so depressed that nothing could cheer me up") and relevant sexual problems (IMET item) by 20.6%. Patients with active disease significantly more often reported severe depressive symptoms (UC: 25.0 vs. 6.4%; CD: 30.7 vs. 8.6%) and sexual problems (UC: 31.4 vs. 8.8%; CD: 42.4 vs. 13.6%) than patients in remission (Tables 2, 3 ). In this respect, the relevance of sufficient therapy to establish remission is revealed to also distinctly ease the associated psychosocial stress of the disease.
Exploratory multivariate analyses were implied for these two vital symptoms of psychosocial impairments in IBD regarding those impairments as covariates and consequences of the disease. Disease activity (CAI N 4/CDAI ≥ 150) was found to be a significant predictor for depressiveness ("rather often", "mostly" or "all of the time" felt depressed) and impairments in sexuality ("considerable", "strong" or "very strong"). For depressiveness, this effect was comparable for UC-and CD patients in univariate analyses (UC: OR = 4.81, 95%-CI: 2.74-8.44; CD: OR = 4.75, 95%-CI: 2.87-7.86). In multivariate analyses, CD patients showed a higher effect (UC: OR = 4.78, 95%-CI: 2.67-8.56; CD: OR = 5.46, 95%-CI: 3.07-9.71) after adjustment for gender, age, disease duration and tobacco smoking. For impairments in sexuality, the effects were similar in univariate analyses, whereas the multivariate analyses (adjusted as above) showed a higher effect for UC-compared to CD patients.
When involvement patterns in UC-and CD patients were additionally entered into the multivariate analyses, they were found to be considerable predictors for both psychosocial indicators, especially for impairments in sexuality (data not shown). Involvement patterns thus seem to be associated with the interactive process of disease activity and psychosocial impairments experienced by the patients. Therefore and because of the possible confounding effects of gender, age, disease duration and smoking associated with disease type and -activity, they were also included in the multivariate analyses for disease activity adjusted for possible confounders (Table 4) .
Involvement patterns did not differ by disease activity for UC-as well as CD patients in unadjusted group comparisons (Tables 2, 3 ). In the multivariate analyses (Table 4) slight, but not significant differences were found between involvement patterns as predictors for disease activity for UC and CD and none of the involvement patterns was particularly correlated with current disease activity. As was expected from the univariate group comparisons, gender, age and disease duration were found to be relevant predictors of current disease activity in the multivariate analyses. UC patients aged 20-29 years were most often affected by disease activity (OR = 2.47, 95%-CI: 1.14-5.31), whereas CD patients aged 40-49 years were most often affected (OR = 1.51, not sign.) by disease activity and patients aged 20-29 years were least often affected (OR = 0.55, not sign.). Gender and smoking were relevant, yet not significant predictors of disease activity in CD patients. However, disease duration was the most influential predictor in CD patients: patients with a disease duration of 10 and more years were most affected by current disease activity (OR = 1.99; 95%-CI: 1.26-3.16).
The clinical status according to the physician's global assessment was also analysed as a predictor of disease activity, and showed to be twice as predictive in UC-than in CD patients, also after multivariate adjustment for gender, age, disease duration and smoking (data not shown). An important objective of the registry was to examine the medical treatment and calculate the current cost of medication and cost of illness for IBD patients in Germany. The frequency of the different drug groups prescribed in the case of CD and UC with regard to disease activity (remission or active disease) are shown in Figs. 1 and 2 . 69.9% of the UC patients and 46.6% of the CD patients received oral aminosalicylate preparations (Table 1 ). An immunosuppressive therapy, such as with Azathioprin/6-Mercaptopurin, was administered to 47.2% of the CD patients and to 25.7% of the UC patients. 8.2% of the CD patients and 2.5% of the UC patients were given TNF-alpha antibodies (at that time Infliximab only was permitted as TNF-alpha antibody in Germany). In CD corticosteroids and in UC corticosteroids and topical medication were associated with higher rates of active disease (CDAI ≥ 150; CAI N 4), but the use of immunosuppressants and aminosalicylates in active disease or in remission was not significantly different ( Figs. 1 and 2) . The calculated relative medication costs as seen by the cost carriers (health insurance) were presented in previous publications and will also be generally discussed here following the complete description of the cohort. 4, 19, 20 
Discussion
The study presents a detailed overview of the health situation and treatment reality of IBD patients in Germany. On account of the online documentation and the link to an input logic analysis, we were able to collect a data set that was as complete as possible. The registry thus provides a good reference database for the treatment of IBD in Germany. The data were analysed from a clinical, a psychosocial and a health care and health economic point of view, and are compared to published data.
Due to the large number of included patients (N = 1032) and centers (k = 26) from all over Germany our IBD collective is hypothesised to be representative for the German population of IBD patients currently treated in primary and also in secondary health care. This registry cohort of IBD patients probably differs a little from the total population of IBD patients in Germany, as some IBD patients in remission or with very light courses of IBD may not have consulted the specialised gastroenterology practices that were included in this registry, but were seen only by general practitioners. In this regard, the registry cohort probably contains a little more severe acute and chronic cases and thus might overestimate the burden of disease and treatment for the total population of IBD patients in Germany. However, it could be regarded as representative for the population of IBD patients treated in gastroenterological practices and hospital outpatient departments.
A general postal survey might overcome these restrictions. An earlier multi-regional postal survey in Germany 13, 12 used random regional samples of DCCV members (Deutsche Crohn/Colitis-Vereinigung, the organisation of IBD patients in Germany) and newspaper advertisements in addition to recruitment in clinical contexts to obtain a more comprehensive sample of the German population of IBD patients. However, the recruitment for that multi-regional survey was also motivated by describing the problems and treatment situation of different groups with a high burden of disease to enable decision makers in health politics to enhance the health care situation in Germany for these chronic diseases. Comparing the two patient cohorts, the patients of the survey cohort comprise larger proportions of female patients, CD patients and patients with longer durations of their diseases. Both cohorts are mostly similar with regard to average age and age distribution, however the age variance is larger in the registry cohort and the registry contains also children younger than 17 years. The survey cohort comprises a remarkable proportion of male CD patients with long disease durations. The registry cohort contains only a small proportion of DCCV members (17%), which might be a good current population estimate for the proportion of patients engaged in the DCCV. In summary, the registry cohort adds representativeness for the population of IBD patients in Germany to the data of earlier studies with regard to gender, social status, disease duration and severity. It is thus a very valuable data source to complement the recent multi-regional survey in Germany.
Patients with ulcerative colitis or Crohn's disease in the registry differ in several aspects. CD patients are more often female, younger with longer durations of disease -a configuration similar to the multi-regional German survey. 13 CD patients more often showed relevant disease activity, hospital admissions and bowel resections and also reported more psychosocial symptoms than the UC patients. The remarkable difference in CD and UC patients concerning the proportion of active smokers will be later discussed in detail. As expected, medication also differed by diagnosis.
The main objective of this study is a description of patients with current disease activity in comparison to patients in remission to give more detailed reference data concerning the burden of disease and treatment of IBD. Patients with ulcerative colitis and current disease activity differed from patients in remission as expected with regard to inflammation (CRP), medication (mostly corticosteroids and topical medication) and also concerning psychosocial symptoms. However they did not differ with regard to involvement patterns or lifestyle factors. CD patients with disease activity were more often female and significantly older than persons in remission, also with longer disease durations and more often had experienced bowel resections. They slightly differed with regard to body-mass index and the proportion of active smokers and more often reported psychosocial symptoms as well.
In contrast to our hypotheses, involvement patterns did not prove to be relevant covariates or predictors for disease activity.
The results very clearly reveal the high psychosocial burden on IBD patients during the course of their disease. The high prevalences of severe depressive symptoms (14.9%) and sexual problems (20.6%) in dependence of clinical disease activity for CD-as well as UC patients reflect the high psychosocial impairments associated with inflammatory bowel diseases.
In the multi-regional survey of IBD patients Hardt et al. (2010) also found a severe negative psychosocial burden in patients with inflammatory bowel diseases. 13 With 1083 participants in the survey, clinically relevant reported depressiveness (HADS depression scale, HADS-D ≥9 points) was found in 23.6% of the IBD patients (with a higher prevalence for male compared to female IBD patients; cases defined by HADS-D cut-off ≥ 11 points: 13.3%) and clinically relevant anxiety (cases defined by HADS-D cut-off ≥11) in 23.8%, with higher frequencies for CD-compared to UC patients. However, in the normal German population, the prevalence of clinically relevant anxiety was found to be 6% (HADS-A≥ 11) and a depressive mood (HADS-D ≥9) was prevalent in 16%. 13, 22 These results of the survey cohort of IBD patients remain stable also in comparison to recent HADS scale reference data 23 for the German normal population (HADS-A ≥ 11: male: 22.4 vs. 5.2%, female: 24.5 vs. 8.1%; HADS-D ≥ 11: male: 17.9 vs. 9.6%, female: 10.8 vs. 9.3%), albeit the IBD cohort is younger than the sample from the normal population. The effect of male IBD patients reporting more often to suffer from psychosocial impairments than female IBD patients is apparent in this comparison and was also confirmed by our exploratory multivariate regression analysis to control for confounding in indicators of psychosocial impairments.
Frequencies of clinically relevant anxiety and depressiveness thus seem to be significantly higher in IBD patients, in particular in patients with current disease activity, compared to the normal German population. For the purpose of analysing the situation, the health care needs and treatment reality of the IBD population in Germany, the IBD survey described by Hardt et al. (2010) intentionally recruited IBD patients from different outpatient-and non-clinical settings. Thus, subsamples for all stages of IBD disease severity with sufficient size for the analyses could be obtained. This resulted in a higher proportion of patients with a severe state of disease and more impairments, yet also a highly educated sample in the survey in comparison to other studies with IBD patients. [24] [25] [26] [27] However, the latter studies also consistently found a higher prevalence of anxiety and the same unusual gender effect compared with the normal population, yet on a lower level than this recent German survey. 13 26.7% of our CD-and 23.3% of the UC patients reported a distinct impairment in their sexuality. 25.5% of the postal survey respondents rated their impairments in sexuality to be strong or total. This earlier postal survey in IBD patients used the original version of the IMET questionnaire with a numeric rating scale from 0 to 10 points whereas the registry implied a version with a new scoring scheme (5 categories as described above). To compare the registry data of the IMET questionnaire with the data of the postal survey, Hardt et al. (2010) used scale percentages (POMPs -percent of maximum possible score 28 ). To consider, these severe depressive symptoms and the sexual problems occur more often in patients with notable disease activity (not in remission). In this respect, the importance of sufficient drug therapy to suppress underlying disease activity is revealed, which may help to ease the correlated psychosocial stress experienced by patients during active disease as well. However, accompanying psychological intervention is often required in addition to IBD-specific drug therapy.
Analyses of the regarded indicators of psychosocial impairments (depressiveness, impairments in sexuality) are presented here with a narrow focus on the results for the substantial associations with disease activity. A key symptom of depressiveness with high specificity and the most relevant indicator for impairments in life activities 13 were chosen to analyse potential confounding in these associations. The more sensitive symptoms of (mental) health impairments (tired, worn out, downhearted) showed similar effects with regard to disease activity, but some of them could as well be symptoms of physical aspects of the disease. The psychosocial indicators are hypothesised to be correlates of clinically relevant disease activity. However, our cross-sectional data do not allow for any causal interpretations of the associations between disease activity and psychosocial impairments. Following the statements 12A-D of the ECCO guideline 3 based on previous evidence it is plausible that the psychosocial impairments in IBD patients observed in this study are rather consequences of these chronic diseases. The apparent association between disease activity and psychosocial symptoms seems to further support that notion of the interpretation. Comprehensive descriptions of the distributions and standardised scale scores of these psychosocial indicators and comprehensive analyses for associations will be presented in a following study with the registry data.
In our cohort, the high rate of smokers amongst the CD patients was striking, although it is known from many studies that smoking is very unfavourable in CD cases, and that abstention from smoking may have a favourable effect on CD that is comparable to the introduction of an immunosuppressive therapy. 29 In our collective, 41.4% of the CD-whereas only 12.5% of the UC patients reported to be active smokers. Hardt et al. reported fewer smokers in their CD collective, with 22.4% of CD patients stated to be active smokers, maybe due to the high percentages of patients with severe courses of disease and to a rather well-educated sample (members of the DCCV patients' organisation). 13, 30 The descriptive analyses did not show large differences in the proportions of active smokers between IBD patients with active disease vs. in remission. However, the multivariate analyses (Table 4) show tobacco smoking as a predictor for disease activity with a small, yet not significant effect (not seen in the descriptive analyses, but in uni-and multivariate regression; Table 4) . Hence, tobacco smoking shows to be a little bit more important as a predictor for disease activity in CD (OR = 1.33) than in UC patients (OR = 1.14).
Smoking also seems to be correlated with psychosocial impairments as the exploratory multivariate analyses reveal. After adjustment for gender, age, disease duration, disease activity and additionally involvement patterns, smoking was still considerably correlated with depressiveness (UC, CD) and reporting impairments in sexuality (UC) and thus a relevant predictor second to disease activity. Apart from appropriate drug therapy, it is of high importance to encourage the smoking CD patients to cease, even if this requires psychological help in the form of withdrawal programmes.
As an additional diagnostic aspect, we analysed also the concordance of the physician's global assessment (PGA) with the usual disease activity indices (CAI/CDAI). The amounts of concordance were fair, but not as good as expected. The physicians rated patients in remission more often in concordance with the disease activity indices similar for UC and CD patients. About one third of those patients with disease activity according to CAI/CDAI values were rated by the physicians as patients in remission. However, about 10% of the patients were not rated by the physicians with regard to disease activity. The physician's global assessment was a better predictor for disease activity according to disease activity indices in UC-than in CD patients (Table 4) , also after multivariate control for gender, age and disease duration.
The general interpretation of these results will be that the symptom-based activity indices can be seen as more reliable and valid than a general clinical impression. Yet, there is a possibility that the physician's clinical judgement might cover other and also relevant aspects of the burden of disease than dichotomous cut-offs in symptom-based activity indices could cover. However, considering our results, the physicians seemed to have underestimated disease activity, maybe also with a possible consequence of undertreatment. A resulting research question might be whether the early detection of disease activity and the success of treatment could be improved by taking more into account the psychosocial aspects of disease.
One objective of this study also was to analyse medical treatment of IBD patients depending on active disease and remission and to calculate the current costs of medication and costs of illness of IBD patients in Germany. The frequency of the different drug groups prescribed to CD and UC patients is shown in previous examinations, with the calculated relative medication costs as seen by the cost carriers (health insurance). 4, 19, 20 We calculated direct costs of IBD from the view of the health care providers. Surgical costs were calculated by the average of disease-related groups (DRGs) for IBD in Germany. Indirect (opportunity) costs like impairments of work productivity were not included in the calculation.
The prescription frequencies were revealed in the statistic calculation of the average medication costs as seen by the cost carriers. 4, 19, 20 The average annual costs for medication amount to € 2582.14 for CD patients and to € 1837.67 for UC patients. The medication costs are substantially influenced by the cost of TNF-alpha antibodies. 57.8% of the medication costs for CD treatment and 29.6% of costs for UC treatment resulted from TNF-alpha antibodies (Infliximab) alone, despite of the relatively low frequency of anti-TNF use (CD 8.2%, UC 2.5%).
In addition, this online survey also recorded all examinations and operations performed during the last three months. Subsequently the overall annual costs of illness for CD and UC were determined as seen by the cost carriers in Germany. 4 Thus, the average annual costs of illness (as seen by the cost carriers) amounted to € 3767.26 for CD (among those 68.5% medications; 20.5% as inpatients) and to € 2477.72 for UC (74% medication; 10% as inpatients). These costs of illness, however, depend substantially on the degree of clinical activity. For CD, the costs of illness range between € 3089.89 and € 5348.22 (for remission or active disease, respectively), and for UC they are between € 1963.37 and € 4204.25. From the cost carriers' point of view, this underlines the necessity of establishing a stable remission phase in the patient by all means possible. A regression analysis published earlier shows that hospital admissions, disease severity and in particular, the administration of TNF-alpha antibodies, all impact upon health care costs. 4 When considering medication costs, there is only one relevant comparable study in Germany by Blumenstein et al. (2008) , which reported data from a regionally limited area around Frankfurt. 11 In the process of that online study, 1024 IBD patients were enrolled between 2005 and 2007. Drug group allocation was carried out for 797 IBD-patients in hospital outpatient departments and gastroenterology practices in the Frankfurt region. In 523 patients, the analysis of the data records with respect to medication costs was performed without differentiation of CD or UC. During this study, the administration of immunosuppressive drugs (Azathioprin/6-MP) in the gastroenterology practices was found to be on less than half of the level compared with outpatient departments of hospitals (15.8% IBD patients with immunosuppressive drugs in practices vs. ca. 38% in hospital outpatient departments), possibly caused by more complicated IBD-patients in the hospital outpatient departments. Infliximab, the only TNF-alpha antibody licensed for CD during this study period, was administered less frequently in general at this point in time (Infliximab in about 2-3% of patients treated in practices and 9.8% of patients treated in hospital outpatient departments). In the sub-group of 523 IBD patients in this study the average annual costs for the drug therapy amounted to € 1826 for practices and was calculated to be € 1849 for hospital outpatient departments.
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The average annual costs of medication calculated in our study are not dissimilar, but were slightly higher for CD patients with € 2582.14 and for UC patients with € 1837.67 which may be due to the higher administration of TNFalpha antibodies in our study.
Other study results (Table 5) , in particular the studies from Germany, found similar costs of drugs. 31 According to Hanauer et al. (1998) the costs for CD patients in the USA were distinctly lower with € 1080 per annum, which may be due to the study being carried out in a hospital outpatient department with a relatively high share in inpatient treatments of more severe cases, or alternatively, due to the fact that at the time the relatively expensive TNF-alpha antibodies were not available for the treatment. 32 In a study carried out in the USA the direct costs for IBDpatients were calculated as well. 33 The average annual CD costs were US$ 8265 and UC costs were US$ 5066, which is slightly higher than shown in our study. The proportional costs for inpatient treatments, amounting to 31.4% for CD and to 34.9% for UC were distinctly higher than in our study (CD 20.5% and UC 10%), which seems to support the appraisal of more efficient outpatient structures in the German health system. However, a real cost comparison is only possible to a limited degree, due to the different remuneration systems in the different countries.
Our nationwide study has certain limitations, which will be discussed here. This study is a cross-sectional study with consecutive recruitment of patients over 17 months. Therefore, a direct interpretation of the association between the health care resources and the disease severity, which was measured by the CDAI and CAI, respectively, is limited. Hence, future studies should focus on the collection of longitudinal data to assess improvements and impairments over time. It is important for the interpretation of the results that cost estimates do not necessarily reflect the actual amount of resources provided by the involved hospitals and physicians, since costs are calculated from the perspective of the German Statutory Health Insurance (SHI).
Our study has covered several aspects of the situation of IBD patients and health care for IBD in Germany. Some aspects are covered much more intensively in other studies (e.g. Hardt et al., 2010) . However, this study provides valuable additional data for Germany as it combines clinical, laboratory and health-care data with psychosocial aspects of inflammatory bowel diseases in a large cohort in secondary health-care units. It thus provides a large dataset of reference data and enhances the possibilities of interpretation for postal survey data as well as for clinical studies.
In conclusion, our study confirms that bodily and psychological impairments and the economic burden of IBD especially in active disease are substantial. Approximately one third of the IBD patients were not in clinical remission, although high rates of immunosuppressive drugs (CD: 47.2%, UC 25.6%) were administered in many patients. This shows a large burden of disease associated with an unexpectedly high (co)morbidity, indicating a reduced health state in IBD patients. The increasing use of biological agents, which have a major impact on the disease costs, will play an important role in future treatment patterns, and health care costs are likely to increase even further in upcoming years. However, it should be considered that with the use of TNF-alpha-inhibitors other costs due to inpatient stays or loss of work productivity might be reduced and patients' satisfaction may improve. 34 Therefore, more information must be collected and analysed on the effects that these innovations may have on disease severity and health related quality of life for IBD patients in a real life settings.
